TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05482087
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALK inhibitor-treated ALK-positive NSCLC treatment
Study: NCT05043376
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard COVID-19 care as per the hospital guidelines
Study: NCT06680089
Drug: [18F]RCCB6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
Study: NCT04379973
Drug: Lipiodol Ultra Fluide®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
Study: NCT05389462
Drug: ADCT-601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05218499
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin
Study: NCT06236295
Drug: SHR6508
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6508 will be administered to all the eligible subjects
Study: NCT05567601
Drug: DOXIL/CAELYX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
Study: NCT06096038
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 300 mg/meter square IV
Study: NCT06165822
Drug: TQB3909 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3909 100mg/tablet.
Study: NCT05595642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC placebo Q2W
Study: NCT03954327
Drug: Placebo Oral Capsule [CEBOCAP]
Normalized name: Placebo Oral Capsule [CEBOCAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
Study: NCT05795517
Drug: HSK31679 medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
Study: NCT00997542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05795517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ，QD，oral，Day1 to week 12
Study: NCT06323174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Study: NCT06315751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in the form of oral capsules with inert ingredients.
Study: NCT05419479
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: every two weeks through an infusion at a dose determined by physician
Study: NCT05340270
Drug: GP
Normalized name: GPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
Study: NCT06130449
Drug: Natesto testosterone intranasal gel
Normalized name: testosterone Nasal Gel [Natesto]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
Study: NCT06130449
Drug: Ayr Saline Nasal Gel
Normalized name: Ayr Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of Ayr (one spray per nostril) will be administered to each participant.
Study: NCT05200104
Drug: PXL065
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXL065 22.5 mg QD
Study: NCT05024305
Drug: TWP-102 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05049980
Drug: Medical treatment with Mifégyne® and MisoOne®
Approvals — FDA: no, EMA: no, PMDA: no
Description: When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
Study: NCT04974359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - capsules
Study: NCT05243654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + standard-of-care MDT
Study: NCT06556745
Drug: BKR-017
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKR-017 is an oral tablet formulation designed to target delivery of sodium butyrate to the colon via colon-targeting technology.
Study: NCT05998642
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5mg/m2 IV
Study: NCT05090371
Drug: Disease modifying treatment (DMT)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
Study: NCT06545526
Drug: celecoxib monotherapy
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
Study: NCT06545526
Drug: celecoxib and metformin combination
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
Study: NCT04765657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injected on Day 1, 90, and 270.
Study: NCT04965597
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05355337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 weeks of treatment with Placebo
Study: NCT06196801
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphodiesterase 5 inhibitors, endothelin receptor antagonist, and parenteral prostacyclin
Study: NCT04537299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looks exactly like the treatment drug, but it contains no active ingredient
Study: NCT06042569
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06796868
Drug: GW117 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW117 Tablets 20mg orally once a day
Study: NCT06796868
Drug: GW117 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW117 Tablets 20mg\*3 orally once a day
Study: NCT06796868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally once a day
Study: NCT06221683
Drug: Recombinant Human Granulocyte Colony-Stimulating Factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ug/kg/d, d1-10, s.c., qd, at 1pm
Study: NCT06799611
Drug: CM336 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
Study: NCT04447911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo per os once daily for 30 days
Study: NCT05456165
Drug: GRT-C901
Approvals — FDA: no, EMA: no, PMDA: no
Description: An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
Study: NCT05456165
Drug: GRT-R902
Approvals — FDA: no, EMA: no, PMDA: no
Description: An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
Study: NCT05456165
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to standard of care.
Study: NCT05994157
Drug: CD38-SADA:177Lu-DOTA Complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
Study: NCT06402721
Drug: BAY3283142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose.
Study: NCT06771180
Drug: Dara-CyBorD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.
Study: NCT06072157
Drug: AK006-IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06072157
Drug: Placebo-IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06072157
Drug: AK006-SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous
Study: NCT05936281
Drug: Genakumab for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/1ml/ vial
Study: NCT05851378
Drug: Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously at time of imaging
Study: NCT04908865
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy will be continued.
Study: NCT05435677
Drug: IcoSema
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
Study: NCT05673148
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive SOC chemotherapy
Study: NCT06556394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via intrathecal injection
Study: NCT06233591
Drug: LP-10 (Liposomal Tacrolimus)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal oral rinse formulation of Tacrolimus
Study: NCT06220019
Drug: TCM
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
Study: NCT05694767
Drug: CM313 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment.
Study: NCT05494723
Drug: YB-1113
Normalized name: YTTERBIUM,YB-169
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
Study: NCT04892342
Drug: ESG401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT06643377
Drug: Enlicitide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05190471
Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of BP1002 monotherapy
Study: NCT05165407
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
Study: NCT04742725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04742725
Drug: Prothione™ (6g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothione is a pro-Glutathione compound includes free-form amino acids
Study: NCT06204991
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting Chemotherapy
Study: NCT06162169
Drug: Midazolam , Rosuvastatin calcium and digoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam , Rosuvastatin calcium and digoxin was administered orally
Study: NCT06576765
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1
Study: NCT05906732
Drug: LQT-1213
Approvals — FDA: no, EMA: no, PMDA: no
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Study: NCT05906732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT05716100
Drug: XEN1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 Capsules
Study: NCT05621811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05886985
Drug: MatriPlax
Approvals — FDA: no, EMA: no, PMDA: no
Description: MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
Study: NCT05689047
Drug: M5717 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Study: NCT05689047
Drug: M5717 660 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Study: NCT06506565
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion during wound care
Study: NCT06696261
Drug: Lianxiaxiaopi Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
Study: NCT06391125
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
Study: NCT04859283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
Study: NCT06702995
Drug: XNW5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous
Study: NCT04901871
Drug: 0.02 mg/kg, age<65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
Study: NCT04901871
Drug: 0.07 mg/kg, age<65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
Study: NCT04901871
Drug: 0.12 mg/kg, age<65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
Study: NCT04901871
Drug: 0.22 mg/kg, age<65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
Study: NCT04901871
Drug: 0.02 mg/kg, age≥65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
Study: NCT04901871
Drug: 0.07 mg/kg, age≥65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
Study: NCT04901871
Drug: 0.12 mg/kg, age≥65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
Study: NCT04901871
Drug: 0.17 mg/kg, age≥65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
Study: NCT04901871
Drug: 0.22 mg/kg, age≥65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
Study: NCT04901871
Drug: 0.27 mg/kg, age≥65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
Study: NCT06453902
Drug: TGRX-678
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
Study: NCT05191706
Drug: Prednisolone Acetate Ophthalmic
Normalized name: prednisolone acetate Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical administration four times a day for 28 days, followed by treatment taper
Study: NCT05087693
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling placebo medication
Study: NCT05369533
Drug: Sinemet Pill
Normalized name: Sinemet Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
Study: NCT05369533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
Study: NCT04084678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral tablets
Study: NCT04909931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second arm : add on placebo for 12 weeks
Study: NCT05761171
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT05761171
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT05761171
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or via NG, NJ, ND or G-tube
Study: NCT04923269
Drug: LY3532226
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04923269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05650567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
Study: NCT05588804
Drug: Broncho-munal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
Study: NCT05588804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
Study: NCT06292806
Drug: FSH-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: controlled ovarian stimulation for IVF
Study: NCT05198778
Drug: URC102
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT04858074
Drug: Hypoestoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
Study: NCT04776044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching tablets for oral intake
Study: NCT05579314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo tablets
Study: NCT05579314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo capsules
Study: NCT04574024
Drug: NBT-NM108
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS Patients received NBT-NM108 at 60 g/day.
Study: NCT05116787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally twice daily
Study: NCT05204667
Drug: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
Study: NCT05204667
Drug: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
Study: NCT05930704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive a single SC injection dose of matching placebo.
Study: NCT05159830
Drug: Placebo oral oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of similar cannabidiol galenic form
Study: NCT00004739
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05061706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules administered orally, once daily.
Study: NCT06557265
Drug: NKX019
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK
Study: NCT06557265
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepletion
Study: NCT05583669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT06190782
Drug: systemic therapy alone
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)
Study: NCT05864105
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
Study: NCT05967689
Drug: TAS6417
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05945680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.